Outlook Therapeutics (id:5399 OTLK)
5.03 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 10:35:46 AM)
Exchange closed, opens in 1 day 22 hours
About Outlook Therapeutics
Market Capitalization 121.35M
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
| Headquarters (address) |
Building F Iselin 08852 NJ United States |
| Phone | 609 619 3990 |
| Website | https://www.outlooktherapeutics.com |
| Employees | 24 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | OTLK |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 4.61 - 12.85 |
| Market Capitalization | 121.35M |
| P/E trailing | -1.05 |
| P/E forward | -2.00 |
| Price/Book | -1.40 |
| Beta | 0.630 |
| EPS | -5.89 |
| EPS United States (ID:6, base:3400) | 24.26 |